Press Releases

Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical research DURHAM, N.C., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Parexel , one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets.
Goldman Sachs’ Partner, Global co-Head of Private Equity Michael Bruun joins as new Director, succeeding current Goldman Sachs Board member Jo Natauri who is retiring from the firm at the end of the year. Life Sciences’ Executive and former CEO John Groetelaars also joins as new Director.
Company receives the highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues.
Addition of new therapeutic expert reflects company’s commitment to drug development in hematology.
New evidence-based reports offer timely analysis and actionable guidance to drug developers bringing critical new therapies to market.
Sign up to receive Parexel news.